{"protocolSection": {"identificationModule": {"nctId": "NCT00585104", "orgStudyIdInfo": {"id": "19266"}, "secondaryIdInfos": [{"id": "IRB# 00019266"}], "organization": {"fullName": "University of Utah", "class": "OTHER"}, "briefTitle": "Myocardial Hemodynamic Effects of Levosimendan", "officialTitle": "Myocardial Hemodynamic Effects of Levosimendan"}, "statusModule": {"statusVerifiedDate": "2013-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-09"}, "primaryCompletionDateStruct": {"date": "2008-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-12-21", "studyFirstSubmitQcDate": "2007-12-21", "studyFirstPostDateStruct": {"date": "2008-01-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-02-11", "resultsFirstSubmitQcDate": "2010-05-17", "resultsFirstPostDateStruct": {"date": "2010-06-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-05-14", "lastUpdatePostDateStruct": {"date": "2013-05-21", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Utah", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This study will test the hypothesis that mechanical efficiency as measured by pressure-volume loop assessment should improve during short-term treatment with intravenous levosimendan.\n\nLevosimendan (SimdaxTM, Abbott Laboratories, Abbott Park, IL) is a calcium sensitizer which has been shown to have beneficial hemodynamic effects in patients with decompensated congestive heart failure (CHF). Levosimendan is a new calcium sensitizer that binds to troponin C. This agent is approved in Europe for treatment of heart failure patients. In the United States, this agent is currently under phase III investigation for intravenous treatment of patients with acutely decompensated HF who have dyspnea at rest or with minimal activity. Levosimendan has been studied in these patients with acute HF and is considered experimental in the United States for this population."}, "conditionsModule": {"conditions": ["Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 10, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "All randomized patients receive drug.", "interventionNames": ["Drug: levosimendan"]}], "interventions": [{"type": "DRUG", "name": "levosimendan", "description": "10-minute infusion", "armGroupLabels": ["1"], "otherNames": ["Simdax"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Left Ventricular End-diastolic Pressure (LVEDP) Using Pressure-volume Catheter.", "description": "Left ventricular end-diastolic pressure (LVEDP) recorded from CD Leycom ConductNT software analysis.", "timeFrame": "From baseline to 30-minutes after levosimendan started."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* All patients will have either a sinus or paced atrial rhythm with atrioventricular synchrony on electrocardiography\n* All patients will have a history of heart failure diagnosed clinically with history of prior symptoms or signs of heart failure with at least one of the following symptoms within the past month: dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, pedal edema\n* In asymptomatic patients, patients may be enrolled if they have at least one of the following clinical signs of heart failure: left ventricular third and/or fourth heart sound, jugular venous pressure \\>7 mmHg, sustained left ventricular impulse, or pulmonary congestion on auscultation\n* all patients will have echocardiographic evidence of left ventricular dysfunction\n\nExclusion Criteria:\n\n* Under age 18", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Andrew Michaels, MD", "affiliation": "University of Utah", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Utah", "city": "Salt Lake City", "state": "Utah", "zip": "84112", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Levosimendan, Compare Heart Function and Metabolism", "description": "All patients received Levosimendan (12mcg/kg IV bolus over 10 minutes, Abbott Laboratories, Abbott Park, IL). All study measurements occur at baseline and 30-minutes after the initiation of levosimendan."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Levosimendan, Compare Heart Function and Metabolism", "description": "All patients received Levosimendan (12mcg/kg IV bolus over 10 minutes, Abbott Laboratories, Abbott Park, IL). All study measurements occur at baseline and 30-minutes after the initiation of levosimendan."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "10"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "10"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "59", "spread": "13.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "2"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}]}]}]}, {"title": "Left Ventricular End Diastolic Pressure (LVEDP)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "18", "spread": "7"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Left Ventricular End-diastolic Pressure (LVEDP) Using Pressure-volume Catheter.", "description": "Left ventricular end-diastolic pressure (LVEDP) recorded from CD Leycom ConductNT software analysis.", "populationDescription": "Ten patients were enrolled. Complete data was available in 6 patients. The primary endpoint was change in left ventricular end diastolic pressure (LVEDP) from baseline to 30-minutes after starting levosimendan. An Intent to Treat (ITT) analysis was performed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "From baseline to 30-minutes after levosimendan started.", "groups": [{"id": "OG000", "title": "Levosimendan, Compare Heart Function and Metabolism", "description": "All patients received Levosimendan (12mcg/kg IV bolus over 10 minutes, Abbott Laboratories, Abbott Park, IL). All study measurements occur at baseline and 30-minutes after the initiation of levosimendan."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.67", "spread": "4.32"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Levosimendan, Compare Heart Function and Metabolism", "description": "All patients received Levosimendan (12mcg/kg IV bolus over 10 minutes, Abbott Laboratories, Abbott Park, IL). All study measurements occur at baseline and 30-minutes after the initiation of levosimendan.", "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 0, "otherNumAtRisk": 10}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Of the ten (10) patients enrolled, only 6 patients completed the study protocol for which we collected data. The data is insufficient to provide a formal summary for publication."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Andrew D. Michaels, MD", "organization": "University of Utah Health Sciences Center", "email": "Andrew.Michaels@hsc.utah.edu", "phone": "(801) 585-5971"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077464", "term": "Simendan"}], "ancestors": [{"id": "D000002316", "term": "Cardiotonic Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058987", "term": "Phosphodiesterase 3 Inhibitors"}, {"id": "D000010726", "term": "Phosphodiesterase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M1805", "name": "Simendan", "asFound": "SLE", "relevance": "HIGH"}, {"id": "M5572", "name": "Cardiotonic Agents", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M29333", "name": "Phosphodiesterase 3 Inhibitors", "relevance": "LOW"}, {"id": "M13629", "name": "Phosphodiesterase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "CaAg", "name": "Cardiotonic Agents"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}